GnRH Antagonist Clinical Trial
Official title:
A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the Progestin-primed Ovarian Stimulation Protocol and the GnRH Antagonist Protocol in Patients Undergoing PGT-A
This randomized trial aims to compare the euploid rate of blastocysts between PPOS and GnRH antagonist protocols in patients undergoing PGT-A. Infertile women who have medical indication for PGT-A will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04414761 -
Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
|
Phase 3 | |
| Recruiting |
NCT03188471 -
Preventive Application of GnRH Antagonist on Early OHSS
|
Phase 4 | |
| Recruiting |
NCT02201914 -
Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF
|
Phase 4 | |
| Completed |
NCT01286051 -
Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles
|
N/A | |
| Not yet recruiting |
NCT05326087 -
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
|
Phase 3 |